NVNO enVVeno Medical Corporation
$6.74▲ +0.22%
Healthcare
Other
Volume 69.6K
Avg Volume (10D) 40.2K
Key Metrics & Fundamentals
Market Cap
$4.68M
P/E Ratio
–
Div Yield
0.00%
52W Range
6.55 - 26.25
% vs 50 MA
-26.62%
% vs 200 MA
-35.02%
RSI-14
32.5
MACD Histogram
-0.0500
Beta (1Y vs SPY)
1.26
Free Cash Flow
-$3.55M
Gross Rev
$0
Gross Profit
$0
EBITDA
-$3.95M
COGS
–
Operating Exp
$3.80M
Operating Income
-$3.80M
EBIT
-$3.80M
Pretax Income
-$3.60M
Net Income
-$3.60M
EPS (Diluted)
-5.37
Price & Volume History
Loading chart…
Recent News
enVVeno Medical Releases New Episode of "WTF" Video Series Featuring CEO Rob Berman
ACCESS Newswire · Oct 21, 2026 8:44 AM ET
enVVeno Medical's First-in-Class enVVe System to Be Featured at The VEINS 2026 Innovation Summit as Company Advances Toward U.S. Pivotal Trial
ACCESS Newswire · Oct 2, 2026 8:44 AM ET
enVVeno Medical CEO Rob Berman Goes Direct to Investors with New "WTF" Video Series
ACCESS Newswire · Sep 16, 2026 8:50 AM ET
enVVeno Medical Presentation from H.C. Wainwright Conference Now Available On-Demand
ACCESS Newswire · Sep 11, 2026 7:00 AM ET
enVVeno Medical Participates in the Virtual Investor 'Why Now' On-Demand Conference
ACCESS Newswire · Aug 27, 2026 9:01 AM ET
Independent Health Economic Study Recently Published in Journal of Vascular Surgery Reports Economic Dominance of enVVeno Medical's Replacement Venous Valve Therapy Compared to Standard of Care Treatments
ACCESS Newswire · Aug 4, 2026 8:46 AM ET
enVVeno Medical Reports Second Quarter 2026 Financial Results and Advances Towards FDA Pivotal Trial for First-in-Class Non-Surgical Replacement Venous Valve
ACCESS Newswire · Jul 31, 2026 8:30 AM ET
Financial Overview - Income Statement
Quarterly
No financial data available. Click Refresh on the ticker to load latest fundamentals.
See NVNO's money flow as a full page
Social Sentiment
Loading Reddit posts…
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.